Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703937 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia
A Phase 3 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 708
- Enrollment target
NCT00703937: Completed Phase 3 study, sponsored by American Regent.
NCT00703937 is a Phase 3 study that has completed, run by American Regent. The registered enrollment target is 708 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00703937, a Phase 3 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 708 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
Primary Outcome
Safety, as defined by the occurence of serious adverse events (SAE's), of FCM compared to SMC in the treatment of IDA in subjects who were not dialysis dependent
Interventions
- DRUG Ferric Carboxymaltose (FCM)
- DRUG Standard Medical Care (SMC) for the treatment of IDA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 708 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
What the finished NCT00703937 record still lists
NCT00703937 is an interventional study that assigns participants to a tested intervention. The registered 708 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Ferric Carboxymaltose (FCM) is the first listed.
NCT00703937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00703937 about?
NCT00703937 is a clinical study titled "Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia". The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
What is the current status of trial NCT00703937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 708 participants. The study started on 2008-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00703937?
The interventions under investigation include: Ferric Carboxymaltose (FCM) (DRUG), Standard Medical Care (SMC) for the treatment of IDA (DRUG).
Who is sponsoring clinical trial NCT00703937?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00703937's enrollment target sits among peer trials
708 505th of 2000 higher than 1,496 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia